Harvard Medical School-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2024

  1. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

  2. Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma

    European Journal of Cancer, Vol. 207

2023

  1. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86

  2. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.

    New England Journal of Medicine, Vol. 389, Núm. 8, pp. 710-721

  3. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2063-2075

2021

  1. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

    ESMO open, Vol. 6, Núm. 3, pp. 100113

2017

  1. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

    Annals of Oncology, Vol. 28, Núm. 12, pp. 2932-2942

2001

  1. Case 2. Skin metastases from prostate adenocarcinoma

    Journal of Clinical Oncology, Vol. 19, Núm. 7, pp. 2099-2100